ByteDance’s Splitting of an AI Pharmaceutical Company: The Calculations Behind It Are Astute
Hello everyone, I’m your financial journalist. Today, we’re going to discuss a news story that may seem like a “cross-industry move” but actually hides many complex strategies: Anew Labs, the AI pharmaceutical company spun off from ByteDance, has just completed a $290 million (about 2 billion RMB) financing round, with a post-financing valuation of $1.5 billion (over 10 billion RMB).
Many people might wonder, “But ByteDance is known for its short videos and games. Why would they get into pharmaceuticals?” or “They’re so wealthy; why would they need their subsidiary to raise funds?”
Don’t worry; the logic behind this is much more intricate and fascinating than it appears on the surface. Today, I’ll break it down in simple terms to explain exactly what strategy ByteDance is pursuing.
---
1. It’s Not About “Selling Off” the Business, but About “Splitting It Up to Grow Independently”
First, let’s clear up a misconception: This is not a case of ByteDance selling off its business. After the financing, ByteDance still holds approximately 56% of Anew Labs’ shares, making it the largest shareholder and the “parent company.”
So why split it up? It’s like a large family with a child who has a special talent for traditional Chinese medicine (in this case, AI pharmaceuticals), while the rest of the family is involved in internet operations (short videos, advertising). If the child stays with the family, they have to follow the family’s rules and use the family’s money, but the other family members might not understand the value of traditional Chinese medicine and might even think the child is spending too much money with slow results, which could cause interference. By setting up the child’s own clinic (an independent company), the parent company still holds the majority stake, but the clinic can have its own team of experts (professional investors) and its own financial independence, potentially leading to an IPO in the future.
Core Logic: ByteDance is focusing on its core internet businesses (such as Douyin and DouBao) and separating off those businesses with strong industry-specific characteristics (like automotive, real estate, AI pharmaceuticals) to allow them to grow independently.
---
2. Why AI Pharmaceuticals? Because It’s a “Heavy” Industry
You might ask, among ByteDance’s many AI products, why choose pharmaceuticals? Look at its current AI portfolio: DouBao, Jimeng, Kouzi, TRAE—these are mostly light-asset products that rely on traffic and computing power. Their model is simple: the more users, the more data, the better the models, and the higher the ad revenue. However, AI pharmaceuticals are completely different:
- Long Development Cycle: Developing a new drug can take 5-10 years or even longer.
- High Barriers to Entry: You need expertise in biochemistry, clinical trials, and regulatory approval, which cannot be achieved by just writing code; it requires a large number of specialized biotech professionals.
- High Risks: A failed internet product might result in a loss of server costs, while a failed drug could result in years of investment wasted and strict legal consequences.
Conclusion: If Anew Labs remained within ByteDance as a department, it would struggle to get the necessary patience and resources. By spinning it off and attracting experienced investors (such as Hillhouse and IDG), ByteDance allows professionals to focus on their area of expertise and utilizes market mechanisms to support this long-term, high-investment business.
---
3. Why Does ByteDance Need Its Subsidiary to Raise Funds Despite Being Wealthy?
This is the most confusing aspect. According to The Wall Street Journal, ByteDance’s net profit is expected to be around $42 billion in 2025, with revenue reaching $120 billion in the first half of 2026. With such financial strength, why would they need Anew Labs to raise funds externally?
The Answer: Money is not for spending; it’s for exchanging for resources. Once Anew Labs becomes independent, its valuation increases significantly. This new valuation:
- Provides incentives for employees through stock options.
- Serves as a foundation for future partnerships with pharmaceutical companies or an independent IPO.
- Turns it from a department of ByteDance into an AI biotech company with its own capital value.
Additionally, by attracting top-tier investors like HSG (formerly Sequoia China), IDG, and Hillhouse, ByteDance gains access to their networks of experts in biotechnology, potential drug partners, and guidance for an IPO.
4. Borrowing $30 Billion While Letting the Subsidiary Raise Funds: What’s the Strategy?
There seems to be a contradiction here:
- Early September: ByteDance borrowed $29.6 billion from banks for AI infrastructure (data centers, chips).
- Now: It’s letting Anew Labs raise funds.
This is actually a dual strategy:
- At the Group Level (ByteDance): Investing in “infrastructure.” In the AI era, computing power is essential for training large models, buying GPUs, and building data centers—these are all capital-intensive investments. Borrowing allows ByteDance to allocate long-term funds to these areas while keeping its cash for dividends, share repurchases, or other investments.
- At the Business Level (Anew Labs): Raising funds allows Anew Labs to focus on its industry-specific needs, such as pharmaceuticals, which require deep industry knowledge and long-term commitment.
**In simple terms, ByteDance is using borrowed funds to build the “highways” (AI infrastructure) for its various “high-performance businesses” (AI companies) to operate on, while letting each business raise its own funds to ensure they can grow independently without overburdening the parent company.”
---
5. Future Prospects: ByteDance is Evolving from an “App Factory” to an “AI Company Factory”
Previously, we focused on ByteDance’s next hit apps (Douyin, TikTok, Jianying). Now, its business model is undergoing a transformation:
- Core Products Being Integrated: General AI products like DouBao, DouBao Work, and TRAE are being integrated into a unified platform, creating an “AI operating system.”
- Vertical Business Separation: Industries with strong industry characteristics (pharmaceuticals, automotive, real estate) are being spun off as independent companies or listed entities.
What does this mean? ByteDance may no longer be just an internet company but an “AI company incubator.” It’s developing core technologies and testing them within its platforms (such as Douyin and Lark). Once these technologies mature, they are spun off to the capital market for further development.
Anew Labs might just be the first example of this trend. In the future, we could see more AI companies emerge from ByteDance, each with ByteDance’s underlying technology but with their own capital structures and industry resources.
In summary: ByteDance’s move is not about a lack of funds but about a strategic upgrade. It uses capital to restructure its business model, combining internet thinking with hard technology and industry-specific strategies. For investors, this means an additional high-valued AI pharmaceutical target. For the industry, it demonstrates how AI can penetrate vertical sectors and become commercially viable. For ByteDance, it retains its core user base while unlocking the potential of its vertical businesses and optimizing its capital structure.
This is a carefully crafted strategy that shows ByteDance’s ambition and stability in its technological development.